BK002 consists of Achyranthes japonica Nakai (AJN) and Melandrium firmum Rohrbach
(MFR) that have been used as herbal medicines in China and Korea. AJN and MFR have …

Stabilization of the G-quadruplexes (G4s) within the androgen receptor (AR) gene promoter
to block transcription may represent an innovative approach to interfere with aberrant AR …

Introduction The androgen/androgen receptor (AR) axis represents a key driver of treatment
resistance in prostate cancer (PCa) patients receiving androgen deprivation therapy (ADT) …

The incidence and mortality from prostate cancer (PCa) are on the rise which poses a major
public health concern worldwide. In this narrative review, we have summarized the …

Background Androgen deprivation therapy (ADT) is still the first-line treatment of prostate
cancer (PCa). However, after a certain period of therapy, primary PCa inevitably progresses …

Patient-derived explant (PDE) culture of solid tumors is increasingly being applied to
preclinical evaluation of novel therapeutics and for biomarker discovery. In this technique …

Prostate cancer is the second-deadliest tumor in men all over the world. Different types of
drugs with various delivery systems and pathways were developed, but no one showed …

Androgen deprivation therapy and second-generation androgen receptor signaling
inhibitors such as enzalutamide are standard treatments for advanced/metastatic prostate …

After the initial androgen deprivation therapy (ADT), part of the prostate cancer may
continuously deteriorate into castration-resistant prostate cancer (CRPC). The majority of …

Enzalutamide (Enz) is a second‐generation androgen receptor (AR) antagonist for
castration‐resistant prostate cancer (CRPC) therapy, and it prolongs survival time in these …